MMP2 and cardiac hypertrophy: Human and neonatal rat cardiomyocytes treated with recombinant leptin were more susceptible to progression of cardiac hypertrophy, as indicated by increased cell size, elevated matrix metalloproteinase-2 (MMP-2) activity, and endothelin-1-induced rise in ROS levels (106, 107).